Clinical trial
Soy Protein/Effexor Hormone Therapy for Prostate Cancer
NCT00354432 · Wake Forest University Health Sciences, Other · Terminated
Key facts
| NCT number | NCT00354432 |
|---|---|
| Title | Soy Protein/Effexor Hormone Therapy for Prostate Cancer |
| Official title | Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men With Prostate Cancer |
| Lead sponsor | Wake Forest University Health Sciences, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hot Flashes, Prostate Cancer |
| Intervention type | Dietary Supplement, Drug |
| Interventions | oral soy protein/isoflavones powder, Venlafaxine, Placebo Powder, Placebo Pill |
| Enrollment | 120 |
| Start date | Feb 1, 2007 |
| Primary completion | Aug 1, 2010 |
| Completion | Aug 1, 2010 |
| First posted | Jul 20, 2006 |
| Last update posted | Sep 28, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: